Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Non-Current Assets (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Other Non-Current Assets for 6 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 90.91% to $1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, down 90.91% year-over-year, with the annual reading at $1000.0 for FY2025, 90.91% down from the prior year.
  • Other Non-Current Assets hit $1000.0 in Q4 2025 for Bolt Biotherapeutics, down from $981000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q3 2023 to a low of $1000.0 in Q4 2025.
  • Historically, Other Non-Current Assets has averaged $1.2 million across 5 years, with a median of $1.6 million in 2021.
  • Biggest five-year swings in Other Non-Current Assets: surged 61.62% in 2022 and later plummeted 99.38% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.0 million in 2021, then surged by 53.55% to $1.6 million in 2022, then rose by 10.31% to $1.8 million in 2023, then tumbled by 99.38% to $11000.0 in 2024, then crashed by 90.91% to $1000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for BOLT at $1000.0 in Q4 2025, $981000.0 in Q3 2025, and $222000.0 in Q2 2025.